0251 GMT - Alcidion's new bull reckons that the healthcare software provider is well placed to deliver positive annual earnings, and maybe even a net profit. Bell Potter analyst Thomas Wakim raises his recommendation on the stock to buy from hold, telling clients in a note that a combination of a cost-cutting restructure with the signing of a large-scale patient-record contract has already delivered modestly positive 1H Ebitda. With A$8 million in licensing revenue scheduled to be recognized in 2H, Wakim anticipates a welcome shift in profitability across Alcidion's full-year result. Bell Potter keeps a A$0.11 target price on the stock, which is down 1.25% at A$0.079. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
March 18, 2025 22:51 ET (02:51 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.